Inclusion Criteria:  Signed informed consent by patients ≥18 years of age and, assent for patients ≥ 12 up to < 18 years of age Patients must have a histologically confirmed diagnosis of non-hematologic tumor with an activating BRAF fusion, CRAF/RAF1 fusion, or CRAF/RAF1 amplification. Patients must have radiographically-recurrent or radiographically-progressive disease that is measurable using the appropriate tumor response criteria (e.g. RECIST version 1.1) Archival tumor tissue (preferably less than 3 years old) or fresh tumor tissue for correlative studies is required If brain metastases are present, they must have been previously treated and be stable as assessed by radiographic imaging  Exclusion Criteria:  Prior therapy with BRAF-, MEK-, or MAPK-directed inhibitor therapy, except for tumor types and indications where such therapy has been approved by the FDA or applicable regulatory authorities Known presence of concurrent activating mutation Patients with current evidence or a history of central serous retinopathy (CSR), retinal vein occlusion (RVO)